WHAT IS CLAIMED IS:

1. A carbohydrate peptide conjugate comprising:

a carrier comprising a dendrimeric poly-Lysine enabling multiple epitopes to be covalently attached thereto.

at least one peptide comprising one T epitope or several identical or different T epitopes,

at least one carbohydrate moiety, or a derivative thereof, containing B epitope, provided it is not a sialoside, or several identical or different epitopes.

2. A conjugate according to claim 1 wherein said dendrimeric poly-Lysine forms a 4 branches star, with an epitope T covalently bound to each lysine of the branches of said carrier.

3. A conjugate according to claim 1 er 2 which comprises at least 3 lysines and up to 15 lysines covalently linked to one another.

4. A conjugate according to any one of claims 1 to 3 wherein to the NH2 end of at least two lysine residues is bound at least one peptide comprising one epitope.

T and wherein the carbohydrate moiety is covalently bound to the end of said peptide opposite to the lysine.

5. A conjugate according to any one of claims 1 to 3 wherein to the NH₂ end of at least two lysine residues is bound at least one carbohydrate residue being not a similoside, optionally substituted and forming a B epitope and wherein the peptide comprising one T epitope is covalently bound to the end of said carbohydrate.

6. A conjugate according to any one of claims 1 to 5 wherein the carbohydrate molety is galactosyl.

7. A conjugate according to any one of claims 1 to 4 which comprises 3 lysino residues, at least 4 epitopes of the T type; which may be the same or different. linked to the NH₂ ends of 2 of the lysine residues and 4 α-galactosyl-Nacetyl-Scrine residues.

8. A conjugate according to claims 1 to 7 wherein the carbohydrate moiety is a galactosyl residue and is substituted by another glycosyl residue.

19

A

Minn H. H. Start Wieff H. H. Start Weets Start

There Tests 1

Hilly March Bent

5

10

15

20

25

A

A

A

F O z

A

A		claim 9. A conjugate according to claims 1 to 8 wherein the carbohydrate is a tumor
Α		antigen. 10. A conjugate according to claims 1 to 9 wherein the epitope T is the 103-
• ,		115 peptide of the VP1 protein of policyirus type 1.
A	5	11. A conjugate according to claims 1 to 10 wherein the carbohydrate is grafted in combination with a tumor peptidic CD8 ⁺ T cell epitope.
A		12. A conjugate according to claims 1 to 8 or 11 wherein the carbohydrate is of
		bacterial or fungal origin. 13. A conjugate according to claim 12 wherein the carbohydrate is from
	10	capsular bacterial polysaccharides sclected from the group consisting of Neisserla meningitis, Haemophilus influenza: Streptocuccus pneumonia and other
		Strepcoccus species, with the exception of sialylated polysaccharides. 14. A conjugate according to claim 1 wherein the carbohydrate is selected
		from the group consisting of Tn antigen di-Tn antigen, tri-Tn antigen, T' antigen and
	15	hexa-Tri antigen. 15. A carbohydrate peptide conjugate comprising: at least one peptide comprising one T epitope, or several identical or different
		T epitopes, and
		at least one carbohydrate molety, or a derivative thereof, containing B epitope,
	20	provided it is not sialogice, or several identical of different epitopes. 16. A carbohydrate peptide conjugate according to claim 15 wherein the
		16. A carbohydrate peptide conjugate according to claim 15 wherein the carbohydrate projety is selected from the group consisting of Tn antigen, di-Tn antigen. Tri-Tn antigen, hexa-Tn antigen and T* antigen.
		antigen. Tri-In antigen. hexa-Tn antigen and T* antigen.

17. Pharmaceutical compesition comprising the conjugate according to any one of claims 1 to 16 and a suitable carrier and adjuvant.

18. Vaccine comprising the conjugate according to any one of claims 1 to 18.

19. Immunogenic composition comprising at least one carbohydrate peptide conjugate according to claims 1 to 16 capable to elect an Immune response against a viral infection caused by a pathogen such as hepatitis virus, HIV or CMV.

۵

A

25

, H

Phone desired theres.

into contact the at least one antibody according to caim 26 and wherein one determines the formation of complexes between this antibody and molecules comprised in the said sample